Tackling Root Causes: Screening and Addressing Non-Medical Drivers of Health
Invalid Access Key! Invalid Access Key!
//
[unable to retrieve full-text content]
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials The Lancet
Comments
Post a Comment